The Alpha Thalassemia Market segment is fundamentally structured around the severity of the $\alpha$-globin gene deletion, which directly dictates the required treatment modality. The four main clinical segments include: Silent Carrier (no symptoms), Alpha Thalassemia Trait (mild anemia, often untreated), Hemoglobin H (HbH) Disease (moderate-to-severe anemia, may require episodic or...